# Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer

> **NCT01375023** · PHASE2 · TERMINATED · sponsor: **European Institute of Oncology** · enrollment: 3 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **RADIATION:** Radiotherapy
- **BIOLOGICAL:** Anti-Thymocyte Globulin

## Key facts

- **NCT ID:** NCT01375023
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2013-07
- **Final completion:** 2013-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Very low accrual rate
- **Last updated:** 2015-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01375023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01375023, "Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01375023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*